Table 1 Select Characteristics of New Users of Palbociclib Identified in the HIRD

From: Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

Characteristicsa All new users of palbociclib New users of palbociclib-fulvestrant New users of palbociclib-letrozole All other new users of palbociclib
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
Overall 2445 100% 566 100% 1159 100% 720 100%
Total duration of follow-up of cohort (in years) 1540 324 812 404
Duration of follow-up (in years) 0.63 0.53 0.57 0.43 0.70 0.58 0.56 0.50
Age at index date (in years) 59.79 11.62 59.47 11.38 59.21 11.27 60.95 12.29
Sex
 Male 53 2.17 < 10 n/a 14 1.21 30 4.17
 Female 2392 97.83 557 98.41 1145 98.79 690 95.83
Calendar year of index date
 2015 791 32.35 99 17.49 456 39.34 236 32.78
 2016 942 38.53 269 47.53 406 35.03 267 37.08
 2017 712 29.12 198 34.98 297 25.63 217 30.14
Geographic region of residence
 Midwest 400 16.36 95 16.78 185 15.96 120 16.67
 South 581 23.76 159 28.09 288 24.85 134 18.61
 Northeast 696 28.47 166 29.33 340 29.34 190 26.39
 West 768 31.41 146 25.80 346 29.85 276 38.33
Secondary malignancy to any site (metastasis) 2137 87.40 496 87.63 1044 90.08 597 82.92
Secondary malignancy to Lymph nodes of head, face, and neck metastasis 690 28.22 154 27.20 356 30.72 180 25.00
Secondary malignancy to Respiratory and digestive system metastasis (includes liver metastasis) 1058 43.27 257 45.41 490 42.28 311 43.19
Secondary malignancy to Metastasis to other specified sites 2017 82.49 463 81.80 978 84.38 576 80.00
Deyo-Charlson comorbidity index (DCI) 8.39 1.90 8.52 1.76 8.48 1.70 8.13 2.25
Advanced stage ER+/HER2- breast cancer 2285 93.46 548 96.82 1083 93.44 654 90.83
Radiation therapy 483 19.75 112 19.79 233 20.10 138 19.17
Chemotherapy 472 19.30 100 17.67 218 18.81 154 21.39
CT related imaging 602 24.62 139 24.56 333 28.73 130 18.06
Number of outpatient visits 39.67 25.20 38.58 23.63 39.51 23.78 40.79 28.42
Aromatase inhibitor 1527 62.45 326 57.60 815 70.32 386 53.61
HER2+ therapy 72 2.94 15 2.65 35 3.02 22 3.06
Tamoxifen 552 22.58 140 24.73 270 23.30 142 19.72
Fulvestrant 621 25.40 238 42.05 112 9.66 271 37.64
Denosumab or pamidronate 836 34.19 206 36.40 359 30.97 271 37.64
Everolimus 150 6.13 40 7.07 52 4.49 58 8.06
Antihypertensives 653 26.71 173 30.57 293 25.28 187 25.97
Corticosteroids 606 24.79 148 26.15 308 26.57 150 20.83
Lipid lowering agent 528 21.60 132 23.32 251 21.66 145 20.14
Pathologic fracture 211 8.63 46 8.13 110 9.49 55 7.64
Pure hypercholesterolemia 215 8.79 48 8.48 105 9.06 62 8.61
  1. Abbreviations: HIRD HealthCore Integrated Research Database, N number, SD standard deviation, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, CT computed tomography
  2. aAll characteristics are measured as presence within six months prior to palbociclib initiation, unless otherwise specified